Egis Pharmaceuticals made a net profit of HUF 18,531 mil in 2012, up 36.4% compared to the previous year. Total sales reached HUF 132,825 mil, which is up 3.01% when compared to the previous year.
Historically, between 2000 and 2012, the company’s net profit reached a high of HUF 18,531 mil in 2012 and a low of HUF 5,540 mil in 2003. Over the last decade the firm's net profit increased by an average of 10.3% a year.
Sales have grown by 5.78% a year on average since 2002. They reached a high of HUF 132,825 mil in 2012 and a low of HUF 65,446 mil in 2000.
The company has been operating with an average EBITDA margin of 19.4% in the last 5 years and average net margin of 12.3%. The firm generated an average return on invested capital of 12.8% for its shareholders over the last five years.
As far as Egis Pharmaceuticals's peers are concerned, Gedeon Richter posted a net profit and sales of HUF 49,265 mil and HUF 326,702 mil in 2012, Krka generated a net profit of EUR 160 mil (with sales of EUR 1,143 mil), and Sanofi-Aventis Czech Republic netted USD CZK 45.2 mil (sales of CZK 7,225 mil).
You can see all the company’s data at Egis Pharmaceuticals profile, or you can download a report on the company in the report section.
Helgi Library 
